Telix Pharmaceuticals Limited (NASDAQ:TLX – Get Free Report)’s share price gapped down before the market opened on Wednesday. The stock had previously closed at $11.16, but opened at $10.25. Telix Pharmaceuticals shares last traded at $10.0550, with a volume of 152,870 shares.
Analysts Set New Price Targets
Several research firms recently issued reports on TLX. Wedbush reissued an “outperform” rating and set a $22.00 price target on shares of Telix Pharmaceuticals in a report on Wednesday. Royal Bank Of Canada raised Telix Pharmaceuticals from a “hold” rating to a “moderate buy” rating in a report on Monday, September 21st. Citigroup reiterated a “buy” rating on shares of Telix Pharmaceuticals in a research report on Thursday, August 20th. HC Wainwright reiterated a “buy” rating and set a $20.00 target price on shares of Telix Pharmaceuticals in a research report on Friday, September 25th. Finally, Weiss Ratings raised Telix Pharmaceuticals from a “sell (d)” rating to a “hold (c-)” rating in a report on Friday, August 21st. Four analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, Telix Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average price target of $20.50.
View Our Latest Stock Report on TLX
Telix Pharmaceuticals Stock Performance
The company has a debt-to-equity ratio of 1.16, a quick ratio of 1.85 and a current ratio of 2.01. The company has a 50 day moving average price of $11.49 and a 200 day moving average price of $10.78.
Institutional Trading of Telix Pharmaceuticals
Institutional investors have recently bought and sold shares of the company. Bank of America Corp DE grew its holdings in Telix Pharmaceuticals by 523.8% in the first quarter. Bank of America Corp DE now owns 10,031 shares of the company’s stock valued at $96,000 after purchasing an additional 8,423 shares during the last quarter. XY Capital Ltd purchased a new position in shares of Telix Pharmaceuticals in the first quarter valued at $120,000. WoodTrust Financial Corp purchased a new position in shares of Telix Pharmaceuticals in the third quarter valued at $186,000. Lazard Asset Management LLC raised its stake in shares of Telix Pharmaceuticals by 15.7% during the 1st quarter. Lazard Asset Management LLC now owns 289,917 shares of the company’s stock worth $2,775,000 after buying an additional 39,400 shares during the last quarter. Finally, Private Advisor Group LLC raised its stake in shares of Telix Pharmaceuticals by 276.3% during the 1st quarter. Private Advisor Group LLC now owns 174,415 shares of the company’s stock worth $1,669,000 after buying an additional 128,070 shares during the last quarter.
About Telix Pharmaceuticals
Telix Pharmaceuticals Limited is a biopharmaceutical company focused on developing and commercializing radiopharmaceuticals and molecularly targeted radiation products. Its programs are designed to support precision medicine by using radioactive compounds to image specific biological targets or deliver radiation directly to diseased tissue.
The company’s principal commercial product is Illuccix, a kit used to prepare gallium Ga 68 gozetotide injection for prostate-specific membrane antigen (PSMA) positron emission tomography (PET) imaging.
See Also
- Five stocks we like better than Telix Pharmaceuticals
- 2 Steel Giants Just Reported Earnings—and Told Very Different Stories
- Swiping to Record Highs: Why Visa Remains a Fortress
- Salesforce Fuels AI Engine With $5.66B Braze Buyout
- ServiceNow Orchestrates AI’s Next Act—Can Earnings Deliver?
Receive News & Ratings for Telix Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Telix Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
